



HALF YEAR REPORT

FOR THE SIX MONTHS TO 30 SEPTEMBER 2024

A close-up photograph of a young woman with long, light brown hair, smiling broadly and showing her teeth. The background is a solid dark blue color. A thick yellow horizontal bar is positioned above the photograph, separating it from the text above.

**PROBIOTIC PIONEERS
FOR A HEALTHIER YOU**



CONTENTS

03

HY25 SUMMARY

04


HALF YEAR REPORT

08

FINANCIAL
STATEMENTS

22

DIRECTORY



HY25 SUMMARY



REVENUE
+25%



**B2B
REVENUE**
+23%



**B2C
REVENUE**
+29%



EBITDA
+ \$0.9m

Note: Movement comparisons above are to the same period of the prior year

NZ PHARMACY CHANNEL

- New distribution partner, Wilson Consumer Products Limited



CONFERENCES BLIS ATTENDED OR PRESENTED AT

- Vitafoods Asia, Bangkok, Thailand
- Amazon Accelerate, Seattle, USA
- NZ Oral Health Association, Auckland, NZ
- Probiota Americas, Salt Lake City, USA

REGULATORY AND R&D PROGRESS

- China regulatory updates to maintain access for BLIS strains to this key market
- Six new independent publications enhancing the BLIS K12™ and BLIS M18™ evidence base

HALF YEAR REPORT

CHAIR & CHIEF EXECUTIVE'S REPORT





Blis Technologies Ltd (Blis) had a favourable first half of the financial year to 30 September 2024 (1HY25) compared to the same period last year (1HY24), despite the challenging macroeconomic backdrop.

In late September 2024 Blis became aware that a key customer had filed a patent for the BLIS K12™ and BLIS M18™ fermentation process in three key jurisdictions. The patent filings remain a concern to Blis. Further details on the patent issue are set out later in this report.

FINANCIAL OVERVIEW

Revenue for 1HY25 was up 25% to \$6m compared to the same period last year, with increases in both the B2B and B2C sales channels. Blis has benefited from a clear focus on the key growth drivers of the business, built around our two 'hero' ingredients of BLIS K12™ and BLIS M18™. The overriding objective remains to deliver sustained profitability for all our key stakeholders.

An unaudited net surplus for 1HY25 of \$0.2m compares with a loss of \$0.7m for the same period last year.

EBITDA was \$0.3m, which can be compared against a loss of \$0.6m for the same period last year. The net surplus and EBITDA for 1HY25 are both stated after inclusion of \$0.3m of expenditure to update for China market access regulation changes. Net cash inflow from operating activities was \$0.7m for 1HY25. Cash and cash equivalents and short-term deposit balances are \$8.9m at 30 September 2024.

B2B REVENUE

B2B revenue of \$3.8m for 1HY25 was a 23% increase on the same period last year, driven by ingredient revenue of \$3.1m. Ingredient revenue grew by 33%, with increases across all our key territories of Europe, North America and Japan as a result of favourable ordering patterns from the dominant customers in each of those markets. Private label sales grew a modest 14% and continues to be an important growth driver for the future for Blis. To complete the B2B picture, royalties were down 17% on the same period last year, reflecting US market weaknesses in line with the

current global trends as noted in the earlier comments.

B2C REVENUE

B2C revenue of \$2.2m was a 29% increase on the same period last year. NZ Pharmacy wholesale continues to show strong growth as our new NZ sales and distribution partner, Wilson Consumer Products Limited, activates the joint business plan with executional excellence. In a challenging environment, the NZ Pharmacy wholesale revenue was up 25% on the same period last year. The growth exceeds the immunity and probiotics category as a whole, and as a result, Blis continues to grow its market share.

Daigou wholesale revenue was down 28% on the same period last year for the second consecutive year, which has necessitated the business to challenge its approach in this area. On 15 November 2024 Blis announced a new partnership with Chinese distributor Orange Daylily to act as the distributor for Blis' branded finished goods product line BLIS Probiotics™ in China. The total wholesale business delivered 41% of our total B2C revenue in 1HY25.



Growth in Direct to Consumer revenues was nominally driven by Blis' Amazon revenue growth of 40%, which is significant given it is 43% of the total B2C business. There have been new products launched and the sales team are fine tuning forecasts as they gauge consumer demand through analysing re-order rates. For example, consumers trading up from Throat Health 30's to Throat Health 60's delivers increased revenue at a higher price point.

Ecommerce through the Blis webstore also showed strong growth of 61% on 1HY24. Several excellent digital campaigns underpinned the result with more planned in the second half of the year with learnings being applied to ensure future campaigns are more

targeted, more cost effective and thus deliver improved return on investment.

REGULATORY AND R&D

The China regulatory access work continues as per the critical path in the project plan. As previously communicated, this will ensure Blis and its strategic business partners continue to have unrestricted access to this key strategic market, which is second in size to the USA market, into 2025 and beyond.

In 1HY25 there has been six new publications on the BLIS® probiotic strains. Key publications related to the ability of specific probiotic sugars to enhance the antimicrobial potency and range of our oral strains, and a clinical

study demonstrating the ability for BLIS K12™ to alleviate oral mucositis symptoms in head and neck cancer patients, highlighting the potential for a new application in a therapeutic setting. This on-going research and development work strengthens our evidence base and provides valuable new data for our sales and marketing activity.

PATENT ISSUE

As noted previously Blis became aware in late September 2024 that a key customer had filed a patent for the BLIS K12™ and BLIS M18™ fermentation process in three key markets. The patent application contained confidential Blis information which had been provided under Non-Disclosure Agreements.



Blis has taken legal advice and is working to have these matters resolved. As part of this process negotiations are currently underway with the key customer. A market update will be provided when the negotiations are complete.

THE BLIS TEAM

It is pleasing to note that in 1HY25 following some minor staffing changes in April 2024 to increase the commercial focus, Blis has continued to enjoy stability in terms of staff turnover. This helps to ensure we have the right blend of new talent, bringing in fresh ideas coupled with the experience and knowledge that more senior Blis team members bring to the table to meet our customers'

needs. Blis continues to invest in the development of its team. A good example of that in action is the intern programme which Blis does every summer, where senior/post graduate University students work alongside John Hale's team in the lab on various research and development initiatives. Lastly it is important to note Blis will be running its annual employee engagement survey in 2HY25. This is an important initiative to get feedback and key insights to ensure we remain a great place to work for key talent.

OUTLOOK

In line with our strategic plan, we will continue to focus on key areas across both B2B and B2C channels to deliver sustainable revenue growth and improved profitability.

As noted earlier, we continue to negotiate with the parties involved in the patent dispute. We will continue to keep shareholders up to date with progress as it is made.

As always, we appreciate your continued support.

Geoff Plunket
Chair
26 November 2024

Scott Johnson
Chief Executive Officer
26 November 2024



FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED
30 SEPTEMBER 2024

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

	NOTES	SIX MONTHS 30 SEP 2024 (UNAUDITED) \$'000	SIX MONTHS 30 SEP 2023 (UNAUDITED) \$'000	12 MONTHS 31 MAR 2024 (AUDITED) \$'000
REVENUES				
Revenue	3.1	5,989	4,777	11,526
Other income	3.2	229	198	447
Total Revenue and Other Income		6,218	4,975	11,973
EXPENSES				
Distribution expenses		153	147	267
Marketing expenses		817	606	1,289
Occupancy expenses		73	45	101
Employee benefits		2,086	2,102	4,219
Raw materials and consumables		1,169	963	2,250
Operating expenses		1,659	1,765	3,120
Finance expenses		12	17	31
Total Expenses		5,969	5,645	11,277
SURPLUS / (DEFICIT) BEFORE TAX		249	(670)	696
Income tax expense		20	-	50
SURPLUS / (DEFICIT) FOR THE PERIOD		229	(670)	646
Other comprehensive income		-	-	-
TOTAL COMPREHENSIVE INCOME / (LOSS)		229	(670)	646
Earnings / (deficit) per share:				
Basic (cents per ordinary share)		0.02	(0.05)	0.05
Diluted (cents per ordinary share)		0.02	(0.05)	0.05

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

	(UNAUDITED)			
	SHARE CAPITAL \$'000	RETAINED EARNINGS/ (DEFICIT) \$'000	SHARE BASED PAYMENTS EQUITY RESERVES \$'000	TOTAL ATTRIBUTABLE TO GROUP \$'000
OPENING EQUITY – 1 APRIL 2024	46,649	(35,241)	80	11,488
Surplus / (deficit) for the year	-	229	-	229
Other comprehensive income	-	-	-	-
Total comprehensive income	-	229	-	229
Employee performance rights plan reserve	-	-	(4)	(4)
	-	-	(4)	(4)
CLOSING EQUITY – 30 SEPTEMBER 2024	46,649	(35,012)	76	11,713
OPENING EQUITY – 1 APRIL 2023	46,649	(35,887)	74	10,836
Surplus / (deficit) for the year	-	(670)	-	(670)
Other comprehensive income	-	-	-	-
Total comprehensive income	-	(670)	-	(670)
Employee performance rights plan reserve	-	-	(1)	(1)
	-	-	(1)	(1)
CLOSING EQUITY – 30 SEPTEMBER 2023	46,649	(36,557)	73	10,165

CONSOLIDATED BALANCE SHEET

AS AT 30 SEPTEMBER 2024

	NOTES	SIX MONTHS 30 SEP 2024 (UNAUDITED) \$'000	SIX MONTHS 30 SEP 2023 (UNAUDITED) \$'000	12 MONTHS 31 MAR 2024 (AUDITED) \$'000
ASSETS				
Current Assets				
Cash and cash equivalents		3,468	3,902	4,272
Short term deposits		5,450	4,000	4,250
Trade and other receivables		1,041	996	1,297
Prepayments		287	224	338
Inventory		820	814	719
NZX Bond		75	75	75
Foreign exchange contracts		16	-	-
TOTAL CURRENT ASSETS		11,157	10,011	10,951
Non Current Assets				
Property, plant and equipment		540	503	502
Finite life intangible assets	4	1,210	969	1,122
Right-of-use-assets		454	470	358
TOTAL NON CURRENT ASSETS		2,204	1,942	1,982
TOTAL ASSETS		13,361	11,953	12,933

Continued overleaf / >>

CONSOLIDATED BALANCE SHEET CONTINUED

AS AT 30 SEPTEMBER 2024

	NOTES	SIX MONTHS 30 SEP 2024 (UNAUDITED) \$'000	SIX MONTHS 30 SEP 2023 (UNAUDITED) \$'000	12 MONTHS 31 MAR 2024 (AUDITED) \$'000
LIABILITIES				
Current Liabilities				
Trade and other payables		1,164	1,268	1,021
Lease liabilities		141	235	177
Foreign exchange contracts		-	15	35
TOTAL CURRENT LIABILITIES		1,305	1,518	1,233
Non Current Liabilities				
Lease liabilities		343	270	212
TOTAL NON CURRENT LIABILITIES		343	270	212
TOTAL LIABILITIES		1,648	1,788	1,445
NET ASSETS		11,713	10,165	11,488
OWNERS EQUITY				
Share capital	5	46,649	46,649	46,649
Retained earnings / (deficits)		(35,012)	(36,557)	(35,241)
Share based payment equity reserves		76	73	80
TOTAL EQUITY		11,713	10,165	11,488



Geoff Plunket
Chair



Barry Richardson
Director

These financial statements have been authorised for issue on 26 November 2024.

CONSOLIDATED STATEMENT OF CASHFLOWS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

	NOTES	SIX MONTHS 30 SEP 2024 (UNAUDITED) \$'000	SIX MONTHS 30 SEP 2023 (UNAUDITED) \$'000	12 MONTHS 31 MAR 2024 (AUDITED) \$'000
CASH FLOWS FROM OPERATING ACTIVITIES				
<i>Cash was provided from / (applied to):</i>				
Receipts from customers		6,338	5,430	11,731
Interest received		94	-	399
Payments to suppliers and employees		(5,676)	(5,450)	(11,044)
Finance costs		(12)	(17)	(31)
Net cash inflow / (outflow) from operating activities	6	744	(37)	1,055
CASH FLOWS FROM INVESTING ACTIVITIES				
<i>Cash was provided from / (applied to):</i>				
Purchase of short term deposits		(1,200)	-	(250)
Purchase of intangible assets		(179)	(177)	(421)
Purchase of property, plant and equipment		(101)	(87)	(149)
Net cash inflow / (outflow) from investing activities		(1,480)	(264)	(819)
CASH FLOWS FROM FINANCING ACTIVITIES				
<i>Cash was provided from / (applied to):</i>				
Repayment of lease liabilities		(118)	(109)	(224)
Net cash inflow / (outflow) from financing activities		(118)	(109)	(224)
Net Increase / (Decrease) in cash held		(854)	(410)	12
Add cash and cash equivalents at start of period		4,272	4,272	4,272
Foreign exchange differences		50	40	(12)
Balance at end of period		3,468	3,902	4,272
COMPRISED OF:				
Cash and cash equivalents		3,468	3,902	4,272
		3,468	3,902	4,272

NOTES TO AND FORMING PART OF THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024

1. BASIS OF REPORTING

Reporting entity

The unaudited consolidated condensed interim financial statements presented are those of Blis Technologies Limited (the "Company") and its subsidiary Blis Functional Foods Limited (the "Group").

The Group's principal activity is developing healthcare products and technologies based on proprietary strains of probiotic bacteria for sale and licensing in New Zealand and overseas.

Statutory base

The Company is a profit-oriented entity, domiciled in New Zealand, registered under the Companies Act 1993 and listed on the New Zealand Stock Exchange. The Company is an FMC reporting entity under the Financial Markets Conduct Act 2013. The financial statements have been prepared in line with the requirements of these Acts and the Financial Reporting Act 2013.

Basis of Preparation

The unaudited consolidated condensed interim financial statements have been prepared in accordance with New Zealand Generally Accepted Accounting Practice ("NZ GAAP") and comply with the New Zealand equivalents to IFRS Accounting Standards ("NZ IFRS"), as appropriate for interim financial statements (NZ IAS 34). The interim financial statements should be read in conjunction with the Group annual report for the year ended 31 March 2024.

The unaudited consolidated condensed interim financial statements were authorised for issue by the Board of Directors on 26 November 2024.

Basis of Measurement

The unaudited consolidated condensed interim financial statements have been prepared on the historical cost basis, except for the derivative financial instruments that are measured at fair value at the end of each reporting period. Historical cost is based on the fair values of the consideration given in exchange for assets.

Accounting policies are selected and applied in a manner which ensures that the resulting financial information satisfies the concepts of relevance and reliability, thereby ensuring that the substance of the underlying transactions or other events is reported.

The same accounting policies and critical judgements, estimates and assumptions are applied in these unaudited consolidated condensed interim financial statements as were applied in the preparation of the Group's consolidated financial statements for the year ended 31 March 2024.

The unaudited consolidated condensed interim financial statements are presented in thousands of New Zealand dollars. The New Zealand dollar is the Group's functional currency.

The unaudited consolidated condensed interim financial statements do not include all the information required for full financial statements.

Critical Judgements, Estimates and Assumptions

In the application of NZ IFRS, the Directors are required to make judgements, estimates and assumptions about carrying values of asset and liabilities that are not readily apparent from other sources. The judgements, estimates and assumptions used in the preparation of these

unaudited consolidated condensed interim financial statements are consistent with those used in the Group's consolidated financial statements for the year ended 31 March 2024.

Significant Accounting Policies

The accounting policies in the unaudited consolidated condensed interim financial statements are the same as those applied in the Group's consolidated financial statements for the year ended 31 March 2024.

The Group has adopted all mandatory new and revised standards and interpretations. None had a material impact on these financial statements.

There are no new or revised standards that are issued but not yet effective that are expected to have a material impact on the Group.

2. SIGNIFICANT TRANSACTIONS AND EVENTS FOR THE CURRENT PERIOD

There were no significant transactions and events that affected the financial performance and financial position of the Group for the six-month period ended 30 September 2024.

3. REVENUE AND OTHER INCOME

3.1 REVENUE

Revenue consists of the following items:

Point in time recognition:

	SIX MONTHS 30 SEP 2024 (UNAUDITED) \$'000	SIX MONTHS 30 SEP 2023 (UNAUDITED) \$'000	12 MONTHS 31 MAR 2024 (AUDITED) \$'000
Sale of goods – domestic sales			
Finished goods	1,062	1,019	1,760
Ingredients	26	37	53
License fee and royalties	9	-	26
Sale of goods – export sales			
Finished goods	1,421	934	2,066
Ingredients	3,077	2,304	6,605
License fee and royalties	394	483	1,016
	5,989	4,777	11,526

3.2 OTHER INCOME

	SIX MONTHS 30 SEP 2024 (UNAUDITED) \$'000	SIX MONTHS 30 SEP 2023 (UNAUDITED) \$'000	12 MONTHS 31 MAR 2024 (AUDITED) \$'000
Grant income	-	-	42
Interest income	229	198	405
	229	198	447

NOTES TO AND FORMING PART OF THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

4. FINITE LIFE INTANGIBLE ASSETS

	TRADEMARKS \$'000	PATENTS \$'000	CAPITALISED DEVELOPMENT \$'000	IT, WEBSITE DEVELOPMENT AND SOFTWARE \$'000	TOTAL \$'000
30 SEPTEMBER 2024 (Unaudited)					
Gross Carrying Amount					
Balance at 1 April 2024	427	1,425	4,121	400	6,373
Additions	74	105	-	-	179
Disposals	-	-	-	-	-
Balance at 30 September 2024	501	1,530	4,121	400	6,552
Accumulated amortisation and impairment					
Balance at 1 April 2024	123	1,055	3,676	397	5,251
Amortisation expense	21	19	48	3	91
Balance at 30 September 2024	144	1,074	3,724	400	5,342
Net book value at 30 September 2024	357	456	397	-	1,210
30 SEPTEMBER 2023 (Unaudited)					
Gross Carrying Amount					
Balance at 1 April 2023	224	1,226	4,103	400	5,953
Additions	57	102	18	-	177
Disposals	-	-	-	-	-
Balance at 30 September 2023	281	1,328	4,121	400	6,130
Accumulated amortisation and impairment					
Balance at 1 April 2023	95	1,022	3,568	379	5,064
Amortisation expense	10	15	63	9	97
Balance at 30 September 2023	105	1,037	3,631	388	5,161
Net book value at 30 September 2023	176	291	490	12	969

	TRADEMARKS \$'000	PATENTS \$'000	CAPITALISED DEVELOPMENT \$'000	IT, WEBSITE DEVELOPMENT AND SOFTWARE \$'000	TOTAL \$'000
31 MARCH 2024 (Audited)					
Gross Carrying Amount					
Balance at 1 April 2023	224	1,226	4,103	400	5,953
Additions	203	199	18	-	420
Disposals	-	-	-	-	-
Balance at 31 March 2024	427	1,425	4,121	400	6,373
Accumulated amortisation and impairment					
Balance at 1 April 2023	95	1,022	3,568	379	5,064
Amortisation expense	28	33	108	18	187
Balance at 31 March 2024	123	1,055	3,676	397	5,251
Net book value at 31 March 2024	304	370	445	3	1,122

5. SHARE CAPITAL

	30 SEP 2024 (UNAUDITED)		30 SEP 2023 (UNAUDITED)		31 MAR 2024 (AUDITED)	
	NO. OF SHARES	\$'000	NO. OF SHARES	\$'000	NO. OF SHARES	\$'000
Balance at the beginning of the period (fully paid)	1,279,301,599	46,649	1,273,801,599	46,469	1,273,801,599	46,469
Shares pursuant to CEO share plan	-	-	-	-	5,500,000	-
Balance at the end of the period	1,279,301,599	46,649	1,273,801,599	46,649	1,279,301,599	46,649

NOTES TO AND FORMING PART OF THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

6. RECONCILIATION OF NET SURPLUS/ (DEFICIT) WITH CASHFLOWS FROM OPERATING ACTIVITIES

	SIX MONTHS 30 SEP 2024 (UNAUDITED) \$'000	SIX MONTHS 30 SEP 2023 (UNAUDITED) \$'000	12 MONTHS 31 MAR 2024 (AUDITED) \$'000
NET SURPLUS / (DEFICIT) FOR THE PERIOD	229	(670)	646
Adjustments for non-cash items:			
Amortisation	91	97	187
Depreciation property, plant and equipment	61	55	117
Depreciation right of use assets	118	112	224
Foreign exchange loss / (gain)	(50)	(40)	10
PSR expense	(4)	(1)	(32)
Loss / (gain) on fair value of foreign exchange contracts	(51)	15	34
CEO share option expense	-	-	38
	394	(432)	1,224
Movement in working capital			
Trade and other receivables	256	447	147
Prepayments	50	115	1
Inventories	(100)	(81)	15
Trade and other payables	144	(86)	(332)
	350	395	(169)
NET CASH INFLOW / (OUTFLOW) FROM OPERATING ACTIVITIES	744	(37)	1,055

7. CAPITAL COMMITMENTS, CONTINGENT ASSETS AND CONTINGENT LIABILITIES

There are \$4k capital commitments as at 30 September 2024 (30 September 2023: \$Nil). There are no material contingent assets or contingent liabilities as at 30 September 2024 (30 September 2023: \$Nil).

8. INVESTMENT IN SUBSIDIARY

SUBSIDIARY	PERCENTAGE HELD		31 MAR 2024	BALANCE DATE	PRINCIPAL ACTIVITY
	30 SEP 2024	30 SEP 2023			
Blis Functional Foods Limited	100%	100%	100%	31 March	Non-trading

9. SEGMENTAL REPORTING

9.1 Operating Segments

The Group is internally reported as a single operating segment to the chief operating decision-maker.

9.2 Revenue from major products and services

The Group's revenues from its major products and services were as follows:

	SIX MONTHS 30 SEP 2024 (UNAUDITED) \$'000	SIX MONTHS 30 SEP 2023 (UNAUDITED) \$'000	12 MONTHS 31 MAR 2024 (AUDITED) \$'000
BLIS products	5,989	4,777	11,526
Non-core business	229	198	447
Total revenue and other income	6,218	4,975	11,973

Non-core revenues include interest received and grant revenue.

NOTES TO AND FORMING PART OF THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

9. SEGMENTAL REPORTING CONTINUED

9.3 Information about geographical areas

	REVENUE FROM EXTERNAL CUSTOMERS			NON CURRENT ASSETS		
	SIX MONTHS 30 SEP 24 (UNAUDITED) \$'000	SIX MONTHS 30 SEP 23 (UNAUDITED) \$'000	12 MONTHS 31 MAR 24 (AUDITED) \$'000	SIX MONTHS 30 SEP 24 (UNAUDITED) \$'000	SIX MONTHS 30 SEP 23 (UNAUDITED) \$'000	12 MONTHS 31 MAR 24 (AUDITED) \$'000
New Zealand	1,097	984	1,839	2,204	1,942	1,982
Asia Pacific (excl. NZ)	886	557	1,183	-	-	-
EMEA	1,738	1,463	5,122	-	-	-
North America	2,268	1,773	3,381	-	-	-
Total revenue	5,989	4,777	11,526	2,204	1,942	1,982
Grant revenue	-	-	42	-	-	-
Other revenue	-	-	-	-	-	-
Interest revenue	229	198	405	-	-	-
Total revenue and other income	6,218	4,975	11,973	2,204	1,942	1,982

Revenues for the six months to 30 September 2024 include \$1,669k, \$1,277k, and \$401k, which arose from sales, license fees and royalties to the Group's three largest customers.

Revenues for the six months to 30 September 2023 include \$1,408k, \$558k, and \$521k, which arose from sales, license fees and royalties to the Group's three largest customers.

Revenues for the year ended 31 March 2024 include \$3,854k, \$1,257k and \$1,220k which arose from sales, license fees and royalties to the Group's three largest customers.

Web sales are allocated to the region where the end consumer is based.

10. SUBSEQUENT EVENTS

There were no subsequent events post 30 September 2024 (2023: Nil).

COMPANY DIRECTORY

FOR THE YEAR ENDED 30 SEPTEMBER 2024

COMPANY NUMBER

1042367

ISSUED CAPITAL

1,279,301,599 Ordinary Shares

REGISTERED OFFICE

Blis Technologies Limited

399 Moray Place

Dunedin Central, Dunedin 9016

SHAREHOLDERS

Listed on the NZX main board

SHARE REGISTRAR

MUFG Corporate Markets

Level 30, PwC Tower

15 Customs Street West

Auckland 1010

DIRECTORS

G Plunket

A Johansen

A McCammon

Dr B Richardson

Dr A Stewart

CHIEF EXECUTIVE

S Johnson

AUDITORS

Deloitte Limited

PO Box 1245

Dunedin

BANKERS

Bank of New Zealand

Dunedin

SOLICITORS

Anderson Lloyd

Private Bag 1959

Dunedin 9054

WEBSITE

www.blis.co.nz

www.blisprobiotics.co.nz

FACEBOOK

www.facebook.com/BLISProbioticsNZ

INSTAGRAM

www.instagram.com/blisprobiotics

LINKEDIN

www.linkedin.com/company/blis-technologies-limited





Physical Address

Blis Technologies Limited
399 Moray Place
Dunedin 9016

Postal Address

PO Box 2208
Dunedin 9044
New Zealand

Email

info@blis.co.nz

Telephone

+64 3 474 0988

www.blis.co.nz